MDMA (Ecstasy) precipitation of panic disorder.
S Pallanti, D Mazzi
Biological Psychiatry July 1, 1992 DOI: 10.1016/0006-3223(92)90145-p (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 3 |
| Population | Patients with panic disorder that began during recreational MDMA (Ecstasy) use |
| Topics | Anxiety MDMA |
| Key findings | In three described patients, panic disorder began during recreational MDMA use and was followed by agoraphobic avoidance that persisted after the drug was stopped. The panic disorder responded well to serotoninergic antidepressant drugs. |
Abstract
The authors describe three patients whose panic disorder began during recreational use of MDMA (Ecstasy) and was subsequently complicated by agoraphobic avoidance that continued autonomously after cessation of the drug. Their panic disorder responded well to serotoninergic antidepressant drugs. Theoretical and practical implications are discussed.
Comparable studies
Other case reports and case series on MDMA for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study High-functioning 24-year-old student with a history of obsessive-compulsive disorder... | 2021 | Case study | n = 1 |
| The treatment of abandonment anxiety with MDMA and LSD Young woman in her mid-twenties with abandonment-related anxiety | 2023 | Retrospective case study | n = 1 |
| MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case study Man in his forties with alcohol and diazepam addiction and complex PTSD from childhood... | 2023 | Case study | n = 1 |
| Utilizing In Vivo and Imaginal Exposure in the Context of MDMA-Assisted Therapy for Social Anxiety Disorder: A Case Report Man in his late 30s with generalized social anxiety disorder | Case report | n = 1 | |
| Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report. 35-year-old Hispanic man with no significant prior mental health history and no prior... | 2018 | Case study | n = 1 |
Citations in the library
Cited by 24
- 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans Addiction May 1, 1994
- Human Pharmacology of 3,4-Methylenedioxymeth-amphetamine ("Ecstasy"): Psychomotor Performance and Subjective Effects Journal of Clinical Psychopharmacology August 1, 2000
- Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d -methamphetamine in healthy volunteers Psychopharmacology February 18, 1999
- No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study Journal of Clinical Psychopharmacology February 1, 2001
- Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies Neuropsychobiology 2000
and 19 more in the library
Cites 4
- Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Journal of Pharmacology and Experimental Therapeutics 1987
- (±3,4-Methylenedioxymethamphetamine Selectively Damages Central Serotonergic Neurons in Nonhuman Primates JAMA July 1, 1988
- A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology 1989
- 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 1986